25 / 25
Page 78
conferenceseries
.com
Volume 8, Issue 3(Suppl)
J Allergy Ther, an open access journal
ISSN: 2155-6121
Allergy-Clinical Immunology 2017
September 07-08, 2017
September 07-08, 2017 | Edinburgh, Scotland
ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY
11
th
International Conference on
J Allergy Ther 2017, 8:3(Suppl)
DOI: 10.4172/2155-6121-C1-006
Audit assessing Omalizumab treatment for Chronic Spontaneous Urticaria to NICE guidelines
Tiffany Lau
1
and
Helen Bourne
2
1
Newcastle Medical School, UK
2
Dept. Immunology & Allergy, Newcastle-Upon-Tyne Hospitals Trust, UK
Background:
Chronic spontaneous urticaria (CSU) is an autoimmune skin disease defined by recurrent hives and angioedema
over 6 weeks with no identifiable triggers. Omalizumab, a recombinant humanised monoclonal antibody, is approved by NICE
as an add on therapy for CSU in patients over 12 years since 2015.
Objectives:
To examine how Omalizumab treatment for CSU meets standards set by NICE guidelines TA339.
Method:
A retrospective study of 37 patients who commenced their first course of sixmonthly subcutaneous injections between
July 2015-January 2017 at the Regional Immunology and Allergy Unit, Newcastle-Upon-Tyne Hospitals Trust were identified
on the department database. 9 patients who have not completed 6 doses were excluded from the treatment part of the analysis.
Results:
Of the 37 patients (age range 19-82, average 48, Female/Male: 33:4) 100% have no response to antihistamine and
montelukast documented and 87% have a significant objective score >28 completed. Of the 36% who did not respond to
treatment at the 4th dose- 20% stopped treatment appropriately, 50% did not stop treatment, 20% were not recorded and 10%
stopped from adverse reactions. Of those who continued to finish 6 doses 80% stopped while 20% did not stop.
Conclusion:
Pre injection standards and treatment stopped after 6 doses were met well. Non-responders did not stop treatment
after the 4
th
dose due to adjustments made to disease flares, other immunosuppressant medications taken during treatment and
extended gaps between doses.
t.lau@newcastle.ac.uk